A remarkable study published in the Journal of Hepatology describes the world's first successful auxiliary liver xenotransplant from a genetically engineered pig to a living person. The patient, a 71-year-old man from China, lived for 171 days, the longest time a porcine liver has ever functioned in a human body. 

This unusual instance not only proves the viability of xenotransplantation—the transplantation of organs from animals to humans—but also highlights the biological and ethical hurdles that must be overcome before such procedures become routine.

Global Health Challenge

According to the World Health Organisation (WHO), thousands of patients die each year while awaiting organ transplants. Hundreds of thousands of people in China suffer from liver disease each year, but only about 6,000 obtained a transplant in 2022. The persistent lack of donor organs has long been one of the most significant concerns in contemporary medicine, prompting scientists to investigate alternatives such as genetic engineering and regenerative therapy. 

In this backdrop, the Chinese research team's success suggests a novel way to close the growing gap between organ demand and supply. Using improvements in gene editing, researchers are seeking to make animal organs more compatible with the human immune system. 

Five-Month Functional Pig Liver 

The patient in this landmark study had hepatitis B-related cirrhosis and hepatocellular cancer, which rendered him unfit for a normal human liver transplant. Surgeons used a genetically altered Diannan tiny pig liver as an auxiliary liver graft, which means it worked alongside the patient's own failing liver. 

The donor pig had been genetically modified 10 times, including the elimination of immune-triggering xenoantigens and the inclusion of human genes to increase compatibility and prevent clotting issues. For nearly a month following surgery, the graft performed important liver functions such as bile production and blood-clotting protein synthesis with no signs of hyperacute or acute rejection. 

However, on day 38, the graft was removed due to the development of xenotransplantation-associated thrombotic microangiopathy (xTMA), a dangerous disorder caused by immune system overactivation and damage to blood vessel walls. Treatment with the complement inhibitor eculizumab and plasma exchange initially stabilised the patient, but persistent gastrointestinal bleeding caused his death on day 171. 

Promise and Peril

"This case proves that a genetically engineered pig liver can function in a human for an extended period," stated lead investigator Dr Beicheng Sun, President of Anhui Medical University's First Affiliated Hospital. "This case represents a significant advancement, highlighting both the potential benefits and the ongoing challenges, particularly related to coagulation dysregulation and immune complications, that require resolution." 

In an accompanying editorial, Dr Heiner Wedemeyer of Hannover Medical School described the case as "a landmark in hepatology", stating that it "shows that a genetically modified porcine liver can engraft and deliver key hepatic functions in a human recipient". 

While this achievement is encouraging, experts concur that xenotransplantation faces significant immunological, ethical, and biosafety problems. There are still concerns regarding long-term infection risks, animal welfare, and regulatory control. 

However, this development could signal the start of a new age in transplant treatment. As regenerative medicine news evolves, the combination of gene editing, immune regulation, and synthetic biology may bring the world closer to long-term remedies for organ failure.